Metagenomi Statistics
Total Valuation
Metagenomi has a market cap or net worth of $55.33 million. The enterprise value is -$146.83 million.
Important Dates
The last earnings date was Monday, March 17, 2025, after market close.
| Earnings Date | Mar 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Metagenomi has 37.38 million shares outstanding. The number of shares has increased by 870.10% in one year.
| Current Share Class | 37.38M |
| Shares Outstanding | 37.38M |
| Shares Change (YoY) | +870.10% |
| Shares Change (QoQ) | +1.47% |
| Owned by Insiders (%) | 10.95% |
| Owned by Institutions (%) | 28.77% |
| Float | 25.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.97 |
| Forward PS | 2.21 |
| PB Ratio | 0.25 |
| P/TBV Ratio | 0.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.91, with a Debt / Equity ratio of 0.19.
| Current Ratio | 6.91 |
| Quick Ratio | 6.73 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -34.69% and return on invested capital (ROIC) is -20.43%.
| Return on Equity (ROE) | -34.69% |
| Return on Assets (ROA) | -16.12% |
| Return on Invested Capital (ROIC) | -20.43% |
| Return on Capital Employed (ROCE) | -30.94% |
| Revenue Per Employee | $258,886 |
| Profits Per Employee | -$386,426 |
| Employee Count | 202 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -5.51M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.70% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -86.70% |
| 50-Day Moving Average | 2.25 |
| 200-Day Moving Average | 2.88 |
| Relative Strength Index (RSI) | 25.07 |
| Average Volume (20 Days) | 380,765 |
Short Selling Information
The latest short interest is 2.57 million, so 6.86% of the outstanding shares have been sold short.
| Short Interest | 2.57M |
| Short Previous Month | 2.64M |
| Short % of Shares Out | 6.86% |
| Short % of Float | 10.17% |
| Short Ratio (days to cover) | 6.21 |
Income Statement
In the last 12 months, Metagenomi had revenue of $52.30 million and -$78.06 million in losses. Loss per share was -$2.36.
| Revenue | 52.30M |
| Gross Profit | -56.88M |
| Operating Income | -88.90M |
| Pretax Income | n/a |
| Net Income | -78.06M |
| EBITDA | -83.49M |
| EBIT | -88.90M |
| Loss Per Share | -$2.36 |
Full Income StatementBalance Sheet
The company has $248.31 million in cash and $45.78 million in debt, giving a net cash position of $202.53 million or $5.42 per share.
| Cash & Cash Equivalents | 248.31M |
| Total Debt | 45.78M |
| Net Cash | 202.53M |
| Net Cash Per Share | $5.42 |
| Equity (Book Value) | 234.86M |
| Book Value Per Share | 6.28 |
| Working Capital | 220.65M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$109.07 million and capital expenditures -$3.11 million, giving a free cash flow of -$112.19 million.
| Operating Cash Flow | -109.07M |
| Capital Expenditures | -3.11M |
| Free Cash Flow | -112.19M |
| FCF Per Share | -$3.00 |
Full Cash Flow StatementMargins
Gross margin is -108.78%, with operating and profit margins of -170.00% and -149.26%.
| Gross Margin | -108.78% |
| Operating Margin | -170.00% |
| Pretax Margin | -159.81% |
| Profit Margin | -149.26% |
| EBITDA Margin | -159.66% |
| EBIT Margin | -170.00% |
| FCF Margin | n/a |
Dividends & Yields
Metagenomi does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -870.10% |
| Shareholder Yield | -870.10% |
| Earnings Yield | -140.14% |
| FCF Yield | -201.41% |
Analyst Forecast
The average price target for Metagenomi is $14.40, which is 872.97% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.40 |
| Price Target Difference | 872.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Metagenomi has an Altman Z-Score of 0.45 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.45 |
| Piotroski F-Score | 3 |